PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|May 12, 2014
Filling and Closing Machine Features Integrated Capping Station
The FXS Combi from Bosch Packaging Technology features an integrated capping station for vials and cartridges.
Advertisement
The FXS Combi, a filling and closing machine from
The FXS Combi operates with a combi filling station with up to six dosing heads. This makes the machine suitable for all common filling technologies, such as peristaltic or rotary slide valve piston pumps as well as the single-use filling technology PreVAS. A combination with different barrier systems is also possible because the FXS Combi is suited for both restricted access barrier systems and isolators. By combining this filling and closing machine with the upstream ATO tub opener and ABO bag opener from Bosch, it can be integrated into fully automated line concepts.
This device is also suited for processing vials for lyophilization, which helps expand the life span of pharmaceuticals. According to the company, filling on a checkweigher during the start-up and run-empty process makes almost 100% of the pharmaceutical liquids usable for filling.
The filling and closing machine was introduced at Interpack 2014.
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement